Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 2001 Nov 1;359(Pt 3):525–535. doi: 10.1042/0264-6021:3590525

Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways.

O J Jupp 1, S M McFarlane 1, H M Anderson 1, A F Littlejohn 1, A A Mohamed 1, R H MacKay 1, P Vandenabeele 1, D J MacEwan 1
PMCID: PMC1222173  PMID: 11672426

Abstract

The pleitropic actions of tumour necrosis factor-alpha (TNF) are transmitted by the type I 55 kDa TNF receptor (TNFR1) and type II 75 kDa TNF receptor (TNFR2), but the signalling mechanisms elicited by these two receptors are not fully understood. In the present study, we report for the first time subtype-specific differential kinase activation in cell models that respond to TNF by undergoing apoptotic cell death. KYM-1 human rhabdomyosarcoma cells and HeLa human cervical epithelial cells, engineered to overexpress TNFR2, displayed c-Jun N-terminal kinase (JNK) activation by wild-type TNF, a TNFR1-specific TNF mutant and a TNFR2-specific mutant TNF in combination with an agonistic TNFR2-specific monoclonal antiserum. A combination of the TNFR2-specific mutant and agonistic antiserum elicited maximal endogenous or exogenous TNFR2 responsiveness. Moreover, alternative expression of a TNFR2 deletion mutant lacking its cytoplasmic domain rendered the cells unable to activate JNK activity through this receptor subtype. The profile of JNK activation by TNFR1 was more transient than that of TNFR2, with TNFR2-induced JNK activity also being more sensitive to the caspase inhibitor, benzyloxycarbonyl-Val-Ala-DL-Asp-fluoromethylketone. Conversely, only activation of the TNFR1 could stimulate mitogen-activated protein kinase (MAPK) or p38 MAPK activities in a time-dependent manner. The role of TNFR2 activation in enhanced apoptotic cell death was confirmed with agonistic monoclonal antisera in cells expressing high levels of TNFR2. Activation of TNFR2 alone elicited cell death, but full TNF-induced death required stimulation of both receptor types. These findings indicate that efficient activation of TNFR2 by soluble TNFs is achievable with co-stimulation by antisera, and that both receptors differentially modulate extracellular signal-regulated kinases contributing to the cytokine's cytotoxic response.

Full Text

The Full Text of this article is available as a PDF (312.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Assefa Z., Vantieghem A., Declercq W., Vandenabeele P., Vandenheede J. R., Merlevede W., de Witte P., Agostinis P. The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin. J Biol Chem. 1999 Mar 26;274(13):8788–8796. doi: 10.1074/jbc.274.13.8788. [DOI] [PubMed] [Google Scholar]
  2. Baxter G. T., Kuo R. C., Jupp O. J., Vandenabeele P., MacEwan D. J. Tumor necrosis factor-alpha mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression. J Biol Chem. 1999 Apr 2;274(14):9539–9547. doi: 10.1074/jbc.274.14.9539. [DOI] [PubMed] [Google Scholar]
  3. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996 Jun 27;334(26):1717–1725. doi: 10.1056/NEJM199606273342607. [DOI] [PubMed] [Google Scholar]
  4. Bigda J., Beletsky I., Brakebusch C., Varfolomeev Y., Engelmann H., Bigda J., Holtmann H., Wallach D. Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J Exp Med. 1994 Aug 1;180(2):445–460. doi: 10.1084/jem.180.2.445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Boone E., Vandevoorde V., De Wilde G., Haegeman G. Activation of p42/p44 mitogen-activated protein kinases (MAPK) and p38 MAPK by tumor necrosis factor (TNF) is mediated through the death domain of the 55-kDa TNF receptor. FEBS Lett. 1998 Dec 18;441(2):275–280. doi: 10.1016/s0014-5793(98)01567-1. [DOI] [PubMed] [Google Scholar]
  6. Brink R., Lodish H. F. Tumor necrosis factor receptor (TNFR)-associated factor 2A (TRAF2A), a TRAF2 splice variant with an extended RING finger domain that inhibits TNFR2-mediated NF-kappaB activation. J Biol Chem. 1998 Feb 13;273(7):4129–4134. doi: 10.1074/jbc.273.7.4129. [DOI] [PubMed] [Google Scholar]
  7. Carpentier I., Declercq W., Malinin N. L., Wallach D., Fiers W., Beyaert R. TRAF2 plays a dual role in NF-kappaB-dependent gene activation by mediating the TNF-induced activation of p38 MAPK and IkappaB kinase pathways. FEBS Lett. 1998 Mar 27;425(2):195–198. doi: 10.1016/s0014-5793(98)00226-9. [DOI] [PubMed] [Google Scholar]
  8. Chan F. K., Chun H. J., Zheng L., Siegel R. M., Bui K. L., Lenardo M. J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000 Jun 30;288(5475):2351–2354. doi: 10.1126/science.288.5475.2351. [DOI] [PubMed] [Google Scholar]
  9. Declercq W., Vandenabeele P., Fiers W. Dimerization of chimeric erythropoietin/75 kDa tumour necrosis factor (TNF) receptors transduces TNF signals: necessity for the 75 kDa-TNF receptor transmembrane domain. Cytokine. 1995 Oct;7(7):701–709. doi: 10.1006/cyto.1995.0082. [DOI] [PubMed] [Google Scholar]
  10. Ferrari D., Los M., Bauer M. K., Vandenabeele P., Wesselborg S., Schulze-Osthoff K. P2Z purinoreceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death. FEBS Lett. 1999 Mar 19;447(1):71–75. doi: 10.1016/s0014-5793(99)00270-7. [DOI] [PubMed] [Google Scholar]
  11. Fiers W., Beyaert R., Boone E., Cornelis S., Declercq W., Decoster E., Denecker G., Depuydt B., De Valck D., De Wilde G. TNF-induced intracellular signaling leading to gene induction or to cytotoxicity by necrosis or by apoptosis. J Inflamm. 1995;47(1-2):67–75. [PubMed] [Google Scholar]
  12. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett. 1991 Jul 22;285(2):199–212. doi: 10.1016/0014-5793(91)80803-b. [DOI] [PubMed] [Google Scholar]
  13. Grell M., Douni E., Wajant H., Löhden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995 Dec 1;83(5):793–802. doi: 10.1016/0092-8674(95)90192-2. [DOI] [PubMed] [Google Scholar]
  14. Grell M., Scheurich P., Meager A., Pfizenmaier K. TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis. Lymphokine Cytokine Res. 1993 Jun;12(3):143–148. [PubMed] [Google Scholar]
  15. Grell M. Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. J Inflamm. 1995;47(1-2):8–17. [PubMed] [Google Scholar]
  16. Grell M., Wajant H., Zimmermann G., Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):570–575. doi: 10.1073/pnas.95.2.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Grell M., Zimmermann G., Gottfried E., Chen C. M., Grünwald U., Huang D. C., Wu Lee Y. H., Dürkop H., Engelmann H., Scheurich P. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 1999 Jun 1;18(11):3034–3043. doi: 10.1093/emboj/18.11.3034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Haas E., Grell M., Wajant H., Scheurich P. Continuous autotropic signaling by membrane-expressed tumor necrosis factor. J Biol Chem. 1999 Jun 18;274(25):18107–18112. doi: 10.1074/jbc.274.25.18107. [DOI] [PubMed] [Google Scholar]
  19. Haridas V., Darnay B. G., Natarajan K., Heller R., Aggarwal B. B. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation. J Immunol. 1998 Apr 1;160(7):3152–3162. [PubMed] [Google Scholar]
  20. Heller R. A., Krönke M. Tumor necrosis factor receptor-mediated signaling pathways. J Cell Biol. 1994 Jul;126(1):5–9. doi: 10.1083/jcb.126.1.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Heller R. A., Song K., Fan N., Chang D. J. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell. 1992 Jul 10;70(1):47–56. doi: 10.1016/0092-8674(92)90532-h. [DOI] [PubMed] [Google Scholar]
  22. Ip Y. T., Davis R. J. Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. Curr Opin Cell Biol. 1998 Apr;10(2):205–219. doi: 10.1016/s0955-0674(98)80143-9. [DOI] [PubMed] [Google Scholar]
  23. Kalb A., Bluethmann H., Moore M. W., Lesslauer W. Tumor necrosis factor receptors (Tnfr) in mouse fibroblasts deficient in Tnfr1 or Tnfr2 are signaling competent and activate the mitogen-activated protein kinase pathway with differential kinetics. J Biol Chem. 1996 Nov 8;271(45):28097–28104. doi: 10.1074/jbc.271.45.28097. [DOI] [PubMed] [Google Scholar]
  24. Ledgerwood E. C., Pober J. S., Bradley J. R. Recent advances in the molecular basis of TNF signal transduction. Lab Invest. 1999 Sep;79(9):1041–1050. [PubMed] [Google Scholar]
  25. Ledgerwood E. C., Prins J. B., Bright N. A., Johnson D. R., Wolfreys K., Pober J. S., O'Rahilly S., Bradley J. R. Tumor necrosis factor is delivered to mitochondria where a tumor necrosis factor-binding protein is localized. Lab Invest. 1998 Dec;78(12):1583–1589. [PubMed] [Google Scholar]
  26. Leeuwenberg J. F., van Tits L. J., Jeunhomme T. M., Buurman W. A. Evidence for exclusive role in signalling of tumour necrosis factor p55 receptor and a potentiating function of p75 receptor on human endothelial cells. Cytokine. 1995 Jul;7(5):457–462. doi: 10.1006/cyto.1995.0062. [DOI] [PubMed] [Google Scholar]
  27. MacEwan D. J. Elevated cPLA2 levels as a mechanism by which the p70 TNF and p75 NGF receptors enhance apoptosis. FEBS Lett. 1996 Jan 22;379(1):77–81. doi: 10.1016/0014-5793(95)01495-0. [DOI] [PubMed] [Google Scholar]
  28. MacEwan D. J., Kim G. D., Milligan G. Agonist regulation of adenylate cyclase activity in neuroblastoma x glioma hybrid NG108-15 cells transfected to co-express adenylate cyclase type II and the beta 2-adrenoceptor. Evidence that adenylate cyclase is the limiting component for receptor-mediated stimulation of adenylate cyclase activity. Biochem J. 1996 Sep 15;318(Pt 3):1033–1039. doi: 10.1042/bj3181033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. MacEwan D. J., Kim G. D., Milligan G. Analysis of the role of receptor number in defining the intrinsic activity and potency of partial agonists in neuroblastoma x glioma hybrid NG108-15 cells transfected to express differing levels of the human beta 2-adrenoceptor. Mol Pharmacol. 1995 Aug;48(2):316–325. [PubMed] [Google Scholar]
  30. MacEwan D. J., Milligan G. Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. Mol Pharmacol. 1996 Dec;50(6):1479–1486. [PubMed] [Google Scholar]
  31. MacEwan D. J., Milligan G. Up-regulation of a constitutively active form of the beta2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. FEBS Lett. 1996 Dec 9;399(1-2):108–112. doi: 10.1016/s0014-5793(96)01300-2. [DOI] [PubMed] [Google Scholar]
  32. Medvedev A. E., Espevik T., Ranges G., Sundan A. Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects. J Biol Chem. 1996 Apr 19;271(16):9778–9784. doi: 10.1074/jbc.271.16.9778. [DOI] [PubMed] [Google Scholar]
  33. Paleolog E. M., Delasalle S. A., Buurman W. A., Feldmann M. Functional activities of receptors for tumor necrosis factor-alpha on human vascular endothelial cells. Blood. 1994 Oct 15;84(8):2578–2590. [PubMed] [Google Scholar]
  34. Paul A., Wilson S., Belham C. M., Robinson C. J., Scott P. H., Gould G. W., Plevin R. Stress-activated protein kinases: activation, regulation and function. Cell Signal. 1997 Sep;9(6):403–410. doi: 10.1016/s0898-6568(97)00042-9. [DOI] [PubMed] [Google Scholar]
  35. Pollock V. P., Lofthouse E. J., Jupp O. J., Gauld S. B., Anderson H. M., MacEwan D. J. Selective down-regulation of the G(q)alpha/G11alpha G-protein family in tumour necrosis factor-alpha induced cell death. Mol Cell Biochem. 2000 Mar;206(1-2):67–74. doi: 10.1023/a:1007066409645. [DOI] [PubMed] [Google Scholar]
  36. Smith C. A., Farrah T., Goodwin R. G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994 Mar 25;76(6):959–962. doi: 10.1016/0092-8674(94)90372-7. [DOI] [PubMed] [Google Scholar]
  37. Takeuchi M., Rothe M., Goeddel D. V. Anatomy of TRAF2. Distinct domains for nuclear factor-kappaB activation and association with tumor necrosis factor signaling proteins. J Biol Chem. 1996 Aug 16;271(33):19935–19942. doi: 10.1074/jbc.271.33.19935. [DOI] [PubMed] [Google Scholar]
  38. Tartaglia L. A., Pennica D., Goeddel D. V. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem. 1993 Sep 5;268(25):18542–18548. [PubMed] [Google Scholar]
  39. Tartaglia L. A., Rothe M., Hu Y. F., Goeddel D. V. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell. 1993 Apr 23;73(2):213–216. doi: 10.1016/0092-8674(93)90222-c. [DOI] [PubMed] [Google Scholar]
  40. Van Ostade X., Vandenabeele P., Everaerdt B., Loetscher H., Gentz R., Brockhaus M., Lesslauer W., Tavernier J., Brouckaert P., Fiers W. Human TNF mutants with selective activity on the p55 receptor. Nature. 1993 Jan 21;361(6409):266–269. doi: 10.1038/361266a0. [DOI] [PubMed] [Google Scholar]
  41. Van Ostade X., Vandenabeele P., Tavernier J., Fiers W. Human tumor necrosis factor mutants with preferential binding to and activity on either the R55 or R75 receptor. Eur J Biochem. 1994 Mar 15;220(3):771–779. doi: 10.1111/j.1432-1033.1994.tb18678.x. [DOI] [PubMed] [Google Scholar]
  42. Vandenabeele P., Declercq W., Beyaert R., Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995 Oct;5(10):392–399. doi: 10.1016/s0962-8924(00)89088-1. [DOI] [PubMed] [Google Scholar]
  43. Vandenabeele P., Declercq W., Vanhaesebroeck B., Grooten J., Fiers W. Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol. 1995 Mar 15;154(6):2904–2913. [PubMed] [Google Scholar]
  44. Vandenabeele P., Declercq W., Vercammen D., Van de Craen M., Grooten J., Loetscher H., Brockhaus M., Lesslauer W., Fiers W. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J Exp Med. 1992 Oct 1;176(4):1015–1024. doi: 10.1084/jem.176.4.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Vandenabeele P., Goossens V., Beyaert R., Declercq W., Grooten J., Vanhaesebroeck B., Van de Craen M., Vercammen D., Depuydt B., Denecker G. Functional requirement of the two TNF receptors for induction of apoptosis in PC60 cells and the role of mitochondria in TNF-induced cytotoxicity. Circ Shock. 1994 Dec;44(4):196–200. [PubMed] [Google Scholar]
  46. Varfolomeev E. E., Schuchmann M., Luria V., Chiannilkulchai N., Beckmann J. S., Mett I. L., Rebrikov D., Brodianski V. M., Kemper O. C., Kollet O. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity. 1998 Aug;9(2):267–276. doi: 10.1016/s1074-7613(00)80609-3. [DOI] [PubMed] [Google Scholar]
  47. Vercammen D., Vandenabeele P., Declercq W., Van de Craen M., Grooten J., Fiers W. Cytotoxicity in L929 murine fibrosarcoma cells after triggering of transfected human p75 tumour necrosis factor (TNF) receptor is mediated by endogenous murine TNF. Cytokine. 1995 Jul;7(5):463–470. doi: 10.1006/cyto.1995.0063. [DOI] [PubMed] [Google Scholar]
  48. Wajant H., Grell M., Scheurich P. TNF receptor associated factors in cytokine signaling. Cytokine Growth Factor Rev. 1999 Mar;10(1):15–26. doi: 10.1016/s1359-6101(98)00023-9. [DOI] [PubMed] [Google Scholar]
  49. Wajant H., Pfeffer K., Pfizenmaier K., Scheurich P. Tumor necrosis factors in 1998. Cytokine Growth Factor Rev. 1998 Sep-Dec;9(3-4):297–302. doi: 10.1016/s1359-6101(98)00013-6. [DOI] [PubMed] [Google Scholar]
  50. Weiss T., Grell M., Hessabi B., Bourteele S., Müller G., Scheurich P., Wajant H. Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site. J Immunol. 1997 Mar 1;158(5):2398–2404. [PubMed] [Google Scholar]
  51. Weiss T., Grell M., Siemienski K., Mühlenbeck F., Dürkop H., Pfizenmaier K., Scheurich P., Wajant H. TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. J Immunol. 1998 Sep 15;161(6):3136–3142. [PubMed] [Google Scholar]
  52. Widmann C., Gerwins P., Johnson N. L., Jarpe M. B., Johnson G. L. MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis. Mol Cell Biol. 1998 Apr;18(4):2416–2429. doi: 10.1128/mcb.18.4.2416. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES